| 000 | 01762 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515130832.0 | ||
| 264 | 0 | _c20080819 | |
| 008 | 200808s 0 0 eng d | ||
| 022 | _a1557-9190 | ||
| 024 | 7 |
_a10.3816/CLM.2008.n.020 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHayslip, John W | |
| 245 | 0 | 0 |
_aCost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission. _h[electronic resource] |
| 260 |
_bClinical lymphoma & myeloma _cJun 2008 |
||
| 300 |
_a166-70 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 |
_aChemotherapy, Adjuvant _xeconomics |
| 650 | 0 | 4 |
_aCosts and Cost Analysis _xmethods |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphoma, Follicular _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 |
_aRemission Induction _xmethods |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 |
_aVincristine _xadministration & dosage |
| 700 | 1 | _aSimpson, Kit N | |
| 773 | 0 |
_tClinical lymphoma & myeloma _gvol. 8 _gno. 3 _gp. 166-70 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3816/CLM.2008.n.020 _zAvailable from publisher's website |
| 999 |
_c18129774 _d18129774 |
||